ChengDa Pharmaceuticals Co. Ltd. Cash Flow-to-Debt Ratio
ChengDa Pharmaceuticals Co. Ltd. cash flow-to-debt ratio. ChengDa Pharmaceuticals Co. Ltd. (301201) has a Cash Flow-to-Debt Ratio of 0.13x as of December 2025, meaning its operating cash flow of CN¥34.02 Million could theoretically repay 0% of its total liabilities (CN¥252.83 Million) in one year. Check 301201 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of ChengDa Pharmaceuticals Co. Ltd. (2019–2025)
Cash flow-to-debt ratio of ChengDa Pharmaceuticals Co. Ltd. from 2019 to 2025. Historical debt coverage capacity for ChengDa Pharmaceuticals Co. Ltd. across 7 annual periods. Check 301201 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
ChengDa Pharmaceuticals Co. Ltd. Cash Flow-to-Debt Ratio by Year (2019–2025)
ChengDa Pharmaceuticals Co. Ltd. cash flow-to-debt ratio by year from 2019 to 2025. Year-by-year debt coverage analysis for ChengDa Pharmaceuticals Co. Ltd.. For the full cash flow conversion analysis, see 301201 cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.13x | CN¥34.02 Million | CN¥252.83 Million | ▲ +36.6% |
| 2024 | 0.10x | CN¥28.65 Million | CN¥290.77 Million | ▼ -91.0% |
| 2023 | 1.09x | CN¥192.07 Million | CN¥176.40 Million | ▲ +141.7% |
| 2022 | 0.45x | CN¥47.67 Million | CN¥105.81 Million | ▼ -16.9% |
| 2021 | 0.54x | CN¥83.14 Million | CN¥153.30 Million | ▼ -68.3% |
| 2020 | 1.71x | CN¥128.97 Million | CN¥75.30 Million | ▲ +379.9% |
| 2019 | 0.36x | CN¥67.52 Million | CN¥189.21 Million | — |